Treatment outcomes of transoral robotic and non-robotic surgeries to treat oropharyngeal, hypopharyngeal, and supraglottic squamous cell carcinoma: A multi-center retrospective observational study in Japan
Treatment outcomes of transoral robotic and non-robotic surgeries to treat oropharyngeal, hypopharyngeal, and supraglottic squamous cell carcinoma: A multi-center retrospective observational study in Japan
复制标题
DOI：
10.1016/j.anl.2021.01.024
复制
发表时间：
2021-04-08
影响因子：
1.7
通讯作者：
Oridate, Nobuhiko
中科院分区：
文献类型：
--
作者：
Sano, Daisuke;Shimizu, Akira;Oridate, Nobuhiko
目的：这项多中心回顾性队列研究的目的是比较日本早期口咽鳞状细胞癌（OPSCC）、下咽鳞状细胞癌（HPSCC）或声门上鳞状细胞癌（SGSCC）患者的经口机器人手术（TORS）和任何非机器人经口手术的疗效和后续术后治疗。材料和方法：比较了接受TORS的早期OPSCC、HPSCC和SGSCC患者的临床信息和手术结果（TORS队列）和接受非机器人经口手术的患者，包括经口视频喉镜手术（TOVS），内镜咽喉手术（ELPS），和经口激光显微手术（TLM）（非机器人队列）。日本头颈癌登记处（登记队列）的数据用于验证比较。主要结果是病理下的阳性边缘的存在和术后治疗的要求，包括放疗或放化疗。结果：68例患者在TORS队列，236例患者在非机器人队列，和1,228例患者在注册队列有资格参加这项研究。TORS队列中的患者更可能患有口咽肿瘤疾病和T2/3疾病（P
Objectives: The aim of this multicenter retrospective cohort study was to compare efficacy and subsequent postoperative treatment between transoral robotic surgery (TORS) and any nonrobotic transoral surgery in Japanese patients with early oropharyngeal squamous cell carcinoma (OPSCC), hypopharyngeal SCC (HPSCC), or supraglottic SCC (SGSCC).Materials and methods: Clinical information and surgical outcomes were compared between patients with early-stage OPSCC, HPSCC, and SGSCC who underwent TORS (TORS cohort) and those who underwent non-robotic transoral surgery, including transoral videolaryngoscopic surgery (TOVS), endoscopic laryngopharyngeal surgery (ELPS), and transoral laser microsurgery (TLM) (non-robotic cohort). The data of the Head and Neck Cancer Registry of Japan (registry cohort) were used to validate the comparison. The main outcomes were the presence of positive margins under pathology and the requirement for postoperative therapy, including radiotherapy or chemoradiotherapy.Results: Sixty-eight patients in the TORS cohort, 236 patients in the non-robotic cohort, and 1,228 patients in the registry cohort were eligible for this study. Patients in the TORS cohort were more likely to have oropharyngeal tumor disease and T2/3 disease than those in the other cohorts (P